SEC Filing Summary

Robert E. Gagnon, a director at Bone Biologics Corp (BBLG), reported a transaction on September 28, 2026. He acquired 113,896 shares of Common Stock through the exercise of a Non-Employee Stock Option granted under the 2015 Equity Incentive Plan. The option had an exercise price of $0.50 per share and an expiration date of September 28, 2036. This transaction was exempt under Rule 16b-3. Following this transaction, Mr. Gagnon directly owns 113,896 shares of Common Stock underlying this option. Additionally, the filing details other holdings of Non-Employee Stock Options with varying exercise prices and expiration dates, all of which are directly owned by Mr. Gagnon.